Trial Profile
A single centre retrospective study of Nivolumab in in non-small cell lung cancer (NSCLC) patients
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 10 Oct 2018
Price :
$35
*
At a glance
- Drugs Nivolumab (Primary)
- Indications Adenocarcinoma; Non-small cell lung cancer; Squamous cell cancer
- Focus Adverse reactions; Therapeutic Use
- 10 Oct 2018 New trial record
- 26 Sep 2018 Results presented at the 19th World Conference on Lung Cancer